SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (BMS) announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren). This antibody-drug conjugate (ADC) treats locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kin...